Screener
Ionis Pharmaceuticals IONS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 2,554,764 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,311,837 | 3,145,402 |
| Accumulated other comprehensive loss | (33,897) | (25,281) |
| Accumulated deficit | (2,838,369) | (2,631,195) |
| Total stockholders' equity | 439,737 | 489,089 |
| Total liabilities and stockholders’ equity | $$2,994,501 | 3,523,836 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's total liabilities & equity?
- Ionis Pharmaceuticals (IONS) reported total liabilities & equity of $2.99B in Q2 2026.
- How has Ionis Pharmaceuticals's total liabilities & equity changed year-over-year?
- Ionis Pharmaceuticals's total liabilities & equity increased by 0.3% year-over-year, from $2.99B to $2.99B.
- What is the long-term trend for Ionis Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total liabilities & equity has grown at a 8.1% compound annual growth rate (CAGR), from $2.39B to $3.52B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Ionis Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude